These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 33188573)

  • 21. Relationships between muscle size, strength, and physical activity in adults with muscular dystrophy.
    Jacques MF; Onambele-Pearson GL; Reeves ND; Stebbings GK; Smith J; Morse CI
    J Cachexia Sarcopenia Muscle; 2018 Dec; 9(6):1042-1052. PubMed ID: 30338901
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The NorthStar Ambulatory Assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials.
    Ricotti V; Ridout DA; Pane M; Main M; Mayhew A; Mercuri E; Manzur AY; Muntoni F;
    J Neurol Neurosurg Psychiatry; 2016 Feb; 87(2):149-55. PubMed ID: 25733532
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of pulmonary function in Duchenne Muscular Dystrophy.
    Mayer OH; Finkel RS; Rummey C; Benton MJ; Glanzman AM; Flickinger J; Lindström BM; Meier T
    Pediatr Pulmonol; 2015 May; 50(5):487-94. PubMed ID: 25755201
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy.
    McDonald CM; Henricson EK; Han JJ; Abresch RT; Nicorici A; Elfring GL; Atkinson L; Reha A; Hirawat S; Miller LL
    Muscle Nerve; 2010 Apr; 41(4):500-10. PubMed ID: 19941337
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Deflazacort treatment of Duchenne muscular dystrophy.
    Biggar WD; Gingras M; Fehlings DL; Harris VA; Steele CA
    J Pediatr; 2001 Jan; 138(1):45-50. PubMed ID: 11148511
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Beyond ambulation: Measuring physical activity in youth with Duchenne muscular dystrophy.
    Killian M; Buchowski MS; Donnelly T; Burnette WB; Markham LW; Slaughter JC; Xu M; Crum K; Damon BM; Soslow JH
    Neuromuscul Disord; 2020 Apr; 30(4):277-282. PubMed ID: 32291149
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Walking and weakness in children: a narrative review of gait and functional ambulation in paediatric neuromuscular disease.
    Kennedy RA; Carroll K; McGinley JL; Paterson KL
    J Foot Ankle Res; 2020 Mar; 13(1):10. PubMed ID: 32122377
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Steroid treatment and the development of scoliosis in males with duchenne muscular dystrophy.
    Alman BA; Raza SN; Biggar WD
    J Bone Joint Surg Am; 2004 Mar; 86(3):519-24. PubMed ID: 14996877
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of gait in Duchenne Muscular Dystrophy: Relation of 3D gait analysis to clinical assessment.
    Romano A; Favetta M; Schirinzi T; Summa S; Minosse S; D'Amico A; Catteruccia M; Petrarca M; Castelli E; Bertini E; Vasco G
    Neuromuscul Disord; 2019 Dec; 29(12):920-929. PubMed ID: 31791868
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fractures and Linear Growth in a Nationwide Cohort of Boys With Duchenne Muscular Dystrophy With and Without Glucocorticoid Treatment: Results From the UK NorthStar Database.
    Joseph S; Wang C; Bushby K; Guglieri M; Horrocks I; Straub V; Ahmed SF; Wong SC;
    JAMA Neurol; 2019 Jun; 76(6):701-709. PubMed ID: 30855644
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Longitudinal Study of Quantitative Muscle Strength and Functional Motor Ability in Ambulatory Boys with Duchenne Muscular Dystrophy.
    Buckon CE; Sienko SE; Fowler EG; Bagley AM; Staudt LA; Sison-Williamson M; Heberer KR; McDonald CM; Sussman MD
    J Neuromuscul Dis; 2022; 9(2):321-334. PubMed ID: 34924398
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Step Activity Monitoring in Boys with Duchenne Muscular Dystrophy and its Correlation with Magnetic Resonance Measures and Functional Performance.
    Nair KS; Lott DJ; Forbes SC; Barnard AM; Willcocks RJ; Senesac CR; Daniels MJ; Harrington AT; Tennekoon GI; Zilke K; Finanger EL; Finkel RS; Rooney WD; Walter GA; Vandenborne K
    J Neuromuscul Dis; 2022; 9(3):423-436. PubMed ID: 35466946
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Normalized grip strength is a sensitive outcome measure through all stages of Duchenne muscular dystrophy.
    Hogrel JY; Decostre V; Ledoux I; de Antonio M; Niks EH; de Groot I; Straub V; Muntoni F; Ricotti V; Voit T; Seferian A; Gidaro T; Servais L
    J Neurol; 2020 Jul; 267(7):2022-2028. PubMed ID: 32206900
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase 3 randomized placebo-controlled trial of tadalafil for Duchenne muscular dystrophy.
    Victor RG; Sweeney HL; Finkel R; McDonald CM; Byrne B; Eagle M; Goemans N; Vandenborne K; Dubrovsky AL; Topaloglu H; Miceli MC; Furlong P; Landry J; Elashoff R; Cox D;
    Neurology; 2017 Oct; 89(17):1811-1820. PubMed ID: 28972192
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The 100-meter timed test: Normative data in healthy males and comparative pilot outcome data for use in Duchenne muscular dystrophy clinical trials.
    Alfano LN; Miller NF; Berry KM; Yin H; Rolf KE; Flanigan KM; Mendell JR; Lowes LP
    Neuromuscul Disord; 2017 May; 27(5):452-457. PubMed ID: 28279570
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Functional changes in Duchenne muscular dystrophy: a 12-month longitudinal cohort study.
    Mazzone E; Vasco G; Sormani MP; Torrente Y; Berardinelli A; Messina S; D'Amico A; Doglio L; Politano L; Cavallaro F; Frosini S; Bello L; Bonfiglio S; Zucchini E; De Sanctis R; Scutifero M; Bianco F; Rossi F; Motta MC; Sacco A; Donati MA; Mongini T; Pini A; Battini R; Pegoraro E; Pane M; Gasperini S; Previtali S; Napolitano S; Martinelli D; Bruno C; Vita G; Comi G; Bertini E; Mercuri E
    Neurology; 2011 Jul; 77(3):250-6. PubMed ID: 21734183
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Skeletal disproportion in glucocorticoid-treated boys with Duchenne muscular dystrophy.
    Kao KT; Joseph S; Capaldi N; Brown S; Di Marco M; Dunne J; Horrocks I; Shepherd S; Ahmed SF; Wong SC
    Eur J Pediatr; 2019 May; 178(5):633-640. PubMed ID: 30762116
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The 6-minute walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter study.
    McDonald CM; Henricson EK; Abresch RT; Florence JM; Eagle M; Gappmaier E; Glanzman AM; ; Spiegel R; Barth J; Elfring G; Reha A; Peltz S
    Muscle Nerve; 2013 Sep; 48(3):343-56. PubMed ID: 23681930
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessing Physical Activity Using Accelerometers in Youth with Duchenne Muscular Dystrophy.
    Arteaga D; Donnelly T; Crum K; Markham L; Killian M; Burnette WB; Soslow J; Buchowski MS
    J Neuromuscul Dis; 2020; 7(3):331-342. PubMed ID: 32417792
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Respiratory and upper limb function as outcome measures in ambulant and non-ambulant subjects with Duchenne muscular dystrophy: A prospective multicentre study.
    Ricotti V; Selby V; Ridout D; Domingos J; Decostre V; Mayhew A; Eagle M; Butler J; Guglieri M; Van der Holst M; Jansen M; Verschuuren JJGM; de Groot IJM; Niks EH; Servais L; Straub V; Voit T; Hogrel JY; Muntoni F
    Neuromuscul Disord; 2019 Apr; 29(4):261-268. PubMed ID: 30852071
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.